Trial Outcomes & Findings for PureWick™ Adolescent Study (NCT NCT06631313)

NCT ID: NCT06631313

Last Updated: 2025-10-17

Results Overview

Capture rate following void (captured as % of urine captured by device and collected in canister, measured by weight). Prior to each void, the weight of the empty urine collection canister and the weight of a dry absorbent pad are collected. Participants void into the device while laying in a bed with the absorbent pad underneath them. After each void, the post-void weight of the urine collection canister and the post-void weight of the absorbent pad are collected. Capture rate is calculated as the weight of captured urine (post-void canister weight - pre-void canister weight) / total urine volume (captured urine (post-void canister weight - pre-void canister weight) + leaked urine (post-void pad weight - pre-void pad weight)) \* 100.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

43 participants

Primary outcome timeframe

Approximately 2 hours after device placement

Results posted on

2025-10-17

Participant Flow

Participant milestones

Participant milestones
Measure
PureWick System
PureWick System: The PureWick System consists of the PureWick Urine Collection System used with either the PureWick Male External Catheter or the PureWick Flex Female External Catheter, which are intended for non-invasive urine output management.
Overall Study
STARTED
43
Overall Study
Female Participants
20
Overall Study
Male Participants
23
Overall Study
Healthcare Professional Placed Device
42
Overall Study
Self-Placed Device
42
Overall Study
COMPLETED
41
Overall Study
NOT COMPLETED
2

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

PureWick™ Adolescent Study

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
PureWick System
n=43 Participants
PureWick System: The PureWick System consists of the PureWick Urine Collection System used with either the PureWick Male External Catheter or the PureWick Flex Female External Catheter, which are intended for non-invasive urine output management.
Age, Categorical
<=18 years
43 Participants
n=99 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=99 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
Age, Continuous
16.8 years
STANDARD_DEVIATION 2.86 • n=99 Participants
Sex: Female, Male
Female
20 Participants
n=99 Participants
Sex: Female, Male
Male
23 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
18 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
24 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants
n=99 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
Race (NIH/OMB)
Asian
1 Participants
n=99 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
Race (NIH/OMB)
Black or African American
20 Participants
n=99 Participants
Race (NIH/OMB)
White
21 Participants
n=99 Participants
Race (NIH/OMB)
More than one race
1 Participants
n=99 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
Region of Enrollment
United States
43 participants
n=99 Participants
BMI
25.37 kg/m2
STANDARD_DEVIATION 5.6 • n=99 Participants

PRIMARY outcome

Timeframe: Approximately 2 hours after device placement

Population: All evaluable participants defined as those who voided with the device in place.

Capture rate following void (captured as % of urine captured by device and collected in canister, measured by weight). Prior to each void, the weight of the empty urine collection canister and the weight of a dry absorbent pad are collected. Participants void into the device while laying in a bed with the absorbent pad underneath them. After each void, the post-void weight of the urine collection canister and the post-void weight of the absorbent pad are collected. Capture rate is calculated as the weight of captured urine (post-void canister weight - pre-void canister weight) / total urine volume (captured urine (post-void canister weight - pre-void canister weight) + leaked urine (post-void pad weight - pre-void pad weight)) \* 100.

Outcome measures

Outcome measures
Measure
Healthcare Professional Placed Device
n=41 Participants
Evaluation of the PureWick System after being placed on the participant by a healthcare professional (HCP).
Self-Placed Device
n=41 Participants
Evaluation of the PureWick System after being self-placed by the participant.
Performance of the PureWick System in Adolescents After HCP Placement and Self-placement
Overall (Females & Males Combined)
90.40 Percentage of urine captured
Standard Deviation 19.31
93.09 Percentage of urine captured
Standard Deviation 13.79
Performance of the PureWick System in Adolescents After HCP Placement and Self-placement
PureWick Flex Female
87.15 Percentage of urine captured
Standard Deviation 17.43
90.41 Percentage of urine captured
Standard Deviation 7.91
Performance of the PureWick System in Adolescents After HCP Placement and Self-placement
PureWick Male
92.95 Percentage of urine captured
Standard Deviation 20.69
95.19 Percentage of urine captured
Standard Deviation 16.95

SECONDARY outcome

Timeframe: Approximately 2 hours after device placement

Population: All enrolled participants that completed a comfort questionnaire

Overall comfort on a 5-point Likert scale ranging from 1- 5 with higher scores indicating a better outcome, where 1 = Very Uncomfortable, 2 = Uncomfortable, 3 = Neither Comfortable or Uncomfortable, 4 = Comfortable, and 5 = Very Comfortable. The last survey question related to likelihood to recommend the device ranged from 1-5 with higher scores indicating a better outcome, where 1 = Very Unlikely, 2 = Unlikely, 3 = Neither Likely Nor Unlikely, 4 - Likely, and 5 = Very Likely.

Outcome measures

Outcome measures
Measure
Healthcare Professional Placed Device
n=18 Participants
Evaluation of the PureWick System after being placed on the participant by a healthcare professional (HCP).
Self-Placed Device
n=23 Participants
Evaluation of the PureWick System after being self-placed by the participant.
Participant Comfort
Device Removal Comfort
4.7 score on a scale
Standard Deviation 0.46
4.0 score on a scale
Standard Deviation 1.02
Participant Comfort
Device Placement Comfort
4.4 score on a scale
Standard Deviation 0.61
4.3 score on a scale
Standard Deviation 0.82
Participant Comfort
Device Voiding Comfort
4.2 score on a scale
Standard Deviation 0.81
4.3 score on a scale
Standard Deviation 0.76
Participant Comfort
Likelihood to Recommend Device to a Loved One
4.3 score on a scale
Standard Deviation 0.69
4.1 score on a scale
Standard Deviation 1.06

SECONDARY outcome

Timeframe: Approximately 2 hours after device placement

Population: All enrolled participants that completed an ease-of-use questionnaire after device self-placement.

Ease of use score on a 5-point Likert scale ranging from 1- 5 with higher scores indicating a better outcome, where 1 = Very Difficult, 2 = Somewhat Difficult, 3 = Average Difficulty, 4 = Somewhat Easy

Outcome measures

Outcome measures
Measure
Healthcare Professional Placed Device
n=19 Participants
Evaluation of the PureWick System after being placed on the participant by a healthcare professional (HCP).
Self-Placed Device
n=23 Participants
Evaluation of the PureWick System after being self-placed by the participant.
Participant Ease of Use
Ease of Use during Device Placement
4.4 score on a scale
Standard Deviation 0.78
4.3 score on a scale
Standard Deviation 0.69
Participant Ease of Use
Ease of Use during Device Removal
5.0 score on a scale
Standard Deviation 0.00
4.7 score on a scale
Standard Deviation 0.65

SECONDARY outcome

Timeframe: Approximately 2 hours after device placement

Population: All enrolled participants that completed an IFU Comprehension questionnaire

Overall IFU comprehension on a 5-point Likert scale ranging from 1- 5 with higher scores indicating a better outcome, where 1 = Strongly Disagree, 2 = Disagree, 3 = Neutral, 4 = Agree, and 5 = Strongly Agree.

Outcome measures

Outcome measures
Measure
Healthcare Professional Placed Device
n=18 Participants
Evaluation of the PureWick System after being placed on the participant by a healthcare professional (HCP).
Self-Placed Device
n=23 Participants
Evaluation of the PureWick System after being self-placed by the participant.
IFU Comprehension
I was able to understand and follow the written instructions
4.8 score on a scale
Standard Deviation 0.43
4.7 score on a scale
Standard Deviation 0.56
IFU Comprehension
I was able to place the PureWick device on myself
4.7 score on a scale
Standard Deviation 0.46
4.6 score on a scale
Standard Deviation 0.66
IFU Comprehension
I was able to understand the pictures in the instructions
4.8 score on a scale
Standard Deviation 0.38
4.7 score on a scale
Standard Deviation 0.45

SECONDARY outcome

Timeframe: From date of first enrollment until the date of last patient completion, approximately 4 weeks

Population: All HCPs who completed an ease-of-use questionnaire after placing at least one device on study participants.

Ease of use score on a 5-point Likert scale ranging from 1- 5 with higher scores indicating a better outcome, where 1 = Very Difficult, 2 = Somewhat Difficult, 3 = Average Difficulty, 4 = Somewhat Easy, and 5 = Very Easy.

Outcome measures

Outcome measures
Measure
Healthcare Professional Placed Device
n=3 Participants
Evaluation of the PureWick System after being placed on the participant by a healthcare professional (HCP).
Self-Placed Device
n=5 Participants
Evaluation of the PureWick System after being self-placed by the participant.
HCP Ease of Use
Ease of Use during Device Removal
5.0 score on a scale
Standard Deviation 0.00
5.0 score on a scale
Standard Deviation 0.00
HCP Ease of Use
Ease of Use during Device Placement
5.0 score on a scale
Standard Deviation 0.00
5.0 score on a scale
Standard Deviation 0.00

Adverse Events

PureWick System

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Director of Clinical Affairs

Becton, Dickinson and Company

Phone: 551-225-1164

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place